Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 8Terminated 2Active not recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Neoplasms 2Fallopian Tube Neoplasms 2Pathologic Complete Response 1Ovarian Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Leiomyosarcoma 1Carcinoma, Ovarian Epithelial 1Adenocarcinoma of the Oesophagus 1

Interventions

Paclitaxel 17Carboplatin 16Magnetic Resonance Spectroscopy 11Taxes 10Specimen Handling 10Bevacizumab 10olaparib 9Gemcitabine 9pembrolizumab 8Immunoglobulin G 7Disulfides 7Biopsy 7liposomal doxorubicin 6Doxorubicin 5cediranib 4Nivolumab 4Cyclophosphamide 4Cisplatin 4oregovomab 3niraparib 3adavosertib 3X-Rays 3Topotecan 3tremelimumab 2rucaparib 2mirvetuximab soravtansine 2berzosertib 2aldesleukin 2Surveys and Questionnaires 2Platinum 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Fallopian Tube Neoplasms × rucaparib × Clear all
NCT02873962 2026-04-01

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
72 enrolled 16 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03522246 2025-06-24

ATHENA

pharmaand GmbH

Phase 3 Active not recruiting
1,097 enrolled 26 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Pathologic Complete Response, Fallopian Tube Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡